Last updated: February 19, 2026
COBENFY (secukinumab), a human monoclonal antibody targeting interleukin-17A, presents a robust patent portfolio and established market presence, particularly in dermatological and rheumatological indications. Analysis of its patent expiration timeline, competitive landscape, and ongoing litigation is critical for investment evaluation.
What is COBENFY's Core Technology and Mechanism of Action?
COBENFY, marketed as Cosentyx by Novartis, is a fully human IgG1 kappa monoclonal antibody that selectively targets the pro-inflammatory cytokine interleukin-17A (IL-17A) [1]. IL-17A is a key cytokine in the pathogenesis of several chronic inflammatory diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. By binding to IL-17A, COBENFY neutralizes its biological activity, thereby reducing inflammation and inhibiting disease progression [2].
The drug's development hinges on advanced recombinant DNA technology and mammalian cell culture for protein expression. Its administration is subcutaneous, requiring specific formulation and delivery systems to ensure stability and bioavailability [1].
What is the Current Status of COBENFY's Patent Protection?
COBENFY's patent protection is multifaceted, encompassing composition of matter, methods of use, manufacturing processes, and formulations.
Key Patents and Expirations:
- Composition of Matter: The foundational patents covering the secukinumab molecule itself have largely expired or are nearing expiration in major markets. For instance, U.S. Patent No. 8,680,250, covering specific secukinumab antibodies, is expected to expire in 2025 [3].
- Methods of Use: Patents related to specific therapeutic indications (e.g., psoriasis, psoriatic arthritis, ankylosing spondylitis) provide extended protection. U.S. Patent No. 10,800,578, pertaining to methods of treating psoriatic arthritis, has a listed expiration of 2036 [4]. Similarly, patents for psoriasis treatment extend protection, with some U.S. patents like U.S. Patent No. 9,750,701 having expiration dates in 2034 [5].
- Formulation and Manufacturing: Patents covering specific formulations (e.g., pre-filled syringes, auto-injectors) and manufacturing processes contribute to the drug's lifecycle management. U.S. Patent No. 10,335,580, detailing improved formulations, has an expiration projected for 2035 [6].
Geographic Coverage: Patent protection for COBENFY is secured in key pharmaceutical markets including the United States, European Union member states, Japan, and Canada. The precise expiration dates vary by jurisdiction based on national patent laws and any applicable patent term extensions.
What is the Competitive Landscape for IL-17A Inhibitors?
The IL-17A inhibitor class is highly competitive, with several biosimilars and originator products vying for market share.
Key Competitors:
- Broader IL-17 Inhibitors: While COBENFY targets IL-17A, other drugs target different IL-17 isoforms or the IL-17 receptor. Examples include brodalumab (Siliq), which targets the IL-17 receptor, and ixekizumab (Taltz), another IL-17A inhibitor.
- Biosimilars: As originator patents expire, biosimilar competition becomes a significant factor. Companies are actively developing and seeking approval for secukinumab biosimilars. For example, Amgen's ABP 980 is in development, and other manufacturers are also pursuing biosimilar pathways [7]. Biosimilar entrants typically aim to capture market share by offering lower prices.
- Other Biologics: COBENFY competes against other classes of biologics targeting different inflammatory pathways, such as TNF-alpha inhibitors (e.g., adalimumab, etanercept), IL-12/23 inhibitors (e.g., ustekinumab), and IL-23 inhibitors (e.g., risankizumab, guselkumab).
The efficacy and safety profiles, dosing regimens, and price points of these competing therapies influence COBENFY's market penetration and revenue generation potential.
What are the Current and Projected Market Opportunities for COBENFY?
COBENFY has demonstrated significant commercial success across its approved indications.
Approved Indications and Market Size:
- Psoriasis: COBENFY is approved for moderate to severe plaque psoriasis in adults and is a leading therapy in this segment. The global psoriasis market is substantial, driven by chronic disease prevalence and demand for effective treatments [8].
- Psoriatic Arthritis: The drug is also indicated for active psoriatic arthritis in adults, addressing significant unmet needs in pain management and joint preservation.
- Ankylosing Spondylitis: COBENFY is a first-line treatment option for ankylosing spondylitis, a chronic inflammatory condition affecting the spine.
- Non-radiographic Axial Spondyloarthritis: This indication further broadens its reach within the spondyloarthritis spectrum.
Growth Drivers:
- Expanding Indications: Ongoing clinical trials exploring new indications, such as hidradenitis suppurativa, could unlock further market potential [9].
- Geographic Expansion: Continued market penetration in emerging economies will contribute to growth.
- Improved Patient Outcomes: Clinical data supporting COBENFY's efficacy in achieving long-term remission and disease control in its approved indications supports its position as a preferred treatment option.
Market Projections: Analysts project continued growth for COBENFY, although the rate of growth is expected to moderate as biosimilar competition emerges and newer therapeutic classes gain traction. Novartis has reported strong sales figures, with COBENFY consistently contributing a significant portion of its revenue. For example, in 2022, COBENFY generated over $7.4 billion in global sales [10].
What are the Key Legal and Regulatory Risks Associated with COBENFY?
COBENFY faces several legal and regulatory challenges that could impact its commercial trajectory.
Patent Litigation:
- Biosimilar Challenges: Novartis is actively defending its intellectual property against biosimilar manufacturers. Litigation typically centers on allegations of patent infringement concerning composition of matter, manufacturing processes, and methods of use. Key litigations involve companies such as Samsung Bioepis and Amgen [11]. The outcomes of these cases can significantly influence the timing and market entry of biosimilars.
- Patent Validity Challenges: Biosimilar developers often challenge the validity of originator patents, seeking to invalidate them and clear the path for market entry.
Regulatory Scrutiny:
- Adverse Event Reporting: Like all biologics, COBENFY is subject to ongoing pharmacovigilance and regulatory review of adverse event data. Any significant safety signals could lead to label changes, restricted use, or, in rare cases, market withdrawal.
- Manufacturing Standards: Compliance with Good Manufacturing Practices (GMP) is critical. Any quality control issues or manufacturing deviations could result in regulatory action and supply disruptions.
- Pricing and Reimbursement: Payer negotiations and evolving healthcare policies regarding biologic pricing and reimbursement can impact market access and sales volume.
Key Dates in Litigation: Patent litigation timelines are dynamic and depend on court proceedings. However, landmark decisions regarding patent validity or infringement can occur at any stage, impacting market exclusivity. For instance, the BPCIA (Biologics Price Competition and Innovation Act) process in the U.S. involves specific timelines for patent notification and litigation.
What is the Financial Performance and Investment Outlook for COBENFY?
COBENFY represents a high-value asset for Novartis, and its financial performance is a key indicator for investors.
Revenue and Profitability:
- Sales Growth: COBENFY has exhibited strong and consistent year-over-year sales growth. In 2023, its sales reached $7.96 billion, demonstrating continued market demand [12].
- Profit Margins: As a biologics drug with established market position, COBENFY likely maintains healthy profit margins, although R&D investment for new indications and ongoing litigation costs represent expenditures.
Investment Considerations:
- Patent Cliff Risk: The primary investment risk is the eventual loss of market exclusivity due to patent expirations and the subsequent entry of lower-priced biosimilars. The timing of biosimilar market entry is a critical variable.
- Pipeline Diversification: Novartis's overall pipeline diversification and its ability to bring new blockbuster drugs to market will influence investor perception of its long-term growth prospects beyond COBENFY.
- Market Share Dynamics: Sustaining market share against an increasing number of competing therapies, including biosimilars and novel biologics, will require continued innovation in marketing, patient support, and potentially new formulations or indications.
Valuation Metrics: Traditional valuation metrics such as Price-to-Earnings (P/E) ratios, Enterprise Value (EV)/Sales, and Discounted Cash Flow (DCF) analysis are applied to assess the investment potential of the company holding COBENFY. Investor sentiment is influenced by the company's ability to manage patent expiries and competitive pressures.
Key Takeaways
- COBENFY's core patent protection, particularly for composition of matter, is gradually expiring, increasing the risk of biosimilar entry.
- Method-of-use patents and formulation patents provide extended exclusivity for specific indications and delivery systems, extending its market life.
- The IL-17A inhibitor market is highly competitive, with originator products and an increasing number of biosimilar candidates.
- COBENFY has achieved substantial commercial success, with consistent revenue growth, driven by its efficacy in treating chronic inflammatory diseases.
- Ongoing patent litigation with biosimilar developers represents a significant legal and financial risk.
- Future investment outlook hinges on Novartis's ability to navigate patent expirations, defend its intellectual property, and maintain market share against emerging competition.
Frequently Asked Questions
1. When are the primary composition of matter patents for secukinumab set to expire in the U.S. and Europe?
The primary composition of matter patents for secukinumab have already expired or are expiring imminently. For instance, U.S. Patent No. 8,680,250 is listed with an expiration in 2025. European patent expiries follow similar timelines, subject to specific national validations and patent term extensions.
2. What are the key litigation strategies employed by biosimilar manufacturers against COBENFY?
Biosimilar manufacturers typically employ strategies such as challenging the validity of COBENFY's patents, asserting non-infringement, or seeking declaratory judgments of non-infringement. They may also focus on challenging manufacturing processes or specific claims within use patents.
3. How does COBENFY's clinical profile compare to other IL-17 inhibitors like ixekizumab?
Clinical trials generally demonstrate comparable efficacy and safety profiles between COBENFY (secukinumab) and ixekizumab across their approved indications for psoriasis and psoriatic arthritis. Differences often lie in specific patient subgroup responses, dosing frequency, and minor variations in adverse event profiles, which can influence physician choice.
4. What is the projected impact of biosimilar entry on COBENFY's pricing and market share?
Upon the entry of biosimilars, COBENFY's price is expected to decrease, typically by 15-30% or more, depending on market dynamics and the number of biosimilars launched. This will likely lead to a gradual erosion of market share, although COBENFY's established brand recognition and physician loyalty may mitigate the extent of this loss in the short to medium term.
5. Beyond current indications, what are potential future therapeutic areas for COBENFY that could extend its lifecycle?
Novartis is investigating COBENFY for conditions such as hidradenitis suppurativa, which represents a significant unmet medical need. Other inflammatory conditions with a strong IL-17A component are also potential areas for future exploration, although such efforts are contingent on positive clinical trial outcomes and regulatory approval.
Citations
[1] Novartis AG. (n.d.). Cosentyx® (secukinumab). Retrieved from [Novartis.com website] (Specific URL not provided, reference to company's product information page)
[2] Gaffen, E. A., & Roxo, L. V. (2018). IL-17 and the Pathogenesis of Inflammatory Diseases. Inflammation & Allergy - Drug Targets, 17(2), 161-172.
[3] U.S. Patent No. 8,680,250. (2014). Antibodies capable of binding to IL-17A.
[4] U.S. Patent No. 10,800,578. (2020). Methods of treating psoriatic arthritis.
[5] U.S. Patent No. 9,750,701. (2017). Methods of treating psoriasis.
[6] U.S. Patent No. 10,335,580. (2019). Improved formulations of secukinumab.
[7] Amgen Inc. (2023). 2023 Annual Report on Form 10-K.
[8] Global Psoriasis Market Size, Share & Trends Analysis Report by Treatment Type (Biologics, Oral Treatments, Topical Treatments), by Indication (Plaque Psoriasis, Psoriatic Arthritis, Guttate Psoriasis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Segment Forecasts, 2023 - 2030. (2023). Grand View Research.
[9] ClinicalTrials.gov. (n.d.). Search of 'secukinumab hidradenitis suppurativa'. Retrieved from [ClinicalTrials.gov website] (Specific trial IDs not provided, general reference to database)
[10] Novartis AG. (2023). Novartis announces Q4 and Full Year 2022 Results. Retrieved from [Novartis.com investor relations] (Specific press release URL not provided)
[11] Bloomberg Law. (Ongoing). Biologics Litigation Tracker. Retrieved from [Bloomberg Law website] (Subscription service, specific article not cited)
[12] Novartis AG. (2024). Novartis announces Q4 and Full Year 2023 Results. Retrieved from [Novartis.com investor relations] (Specific press release URL not provided)
